The Lancet has published two papers on eczema, one including an adolescent cohort (children over the age of 12 years). The Archivist thought these two novel treatments needed discussion. They may well get into the paediatric world. Nemolizumab is an interleukin (IL)−31 receptor subunit α antagonist, and it acts by inhibiting the IL-31 pathway, which can cause the inflammation and itch in eczema. ARCADIA 1 and ARCADIA 2 were two randomised, double-blind, placebo-controlled phase 3 trials in adult and adolescent participants (aged ≥12 years) over 12 months using nemolizumab. These subjects not only had with moderate-to-severe itchy, atopic dermatitis, but …